Necroptosis in Alzheimer's Disease

Necroptosis is a programmed form of cell death that plays an increasingly recognized role in the pathogenesis of Alzheimer’s disease (AD). Unlike apoptosis, which is a non-inflammatory form of cell death, necroptosis is characterized by cellular swelling, membrane rupture, and the release of intracellular contents that trigger neuroinflammation. This distinctive feature makes necroptosis particularly relevant to AD, where chronic neuroinflammation is a hallmark pathological feature.

Overview of Necroptosis

Necroptosis is mediated by a core signaling cascade involving receptor-interacting protein kinase 1 (RIPK1), RIPK3, and mixed lineage kinase domain-like protein (MLKL)^{1Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury2005 · Nature Chemical Biology · DOI 10.1038/nchembio711Open reference}. This pathway can be activated by various stimuli, including tumor necrosis factor alpha (TNF-α), Fas ligand, Toll-like receptor engagement, and viral infections^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}. The activation of this pathway leads to the phosphorylation and oligomerization of MLKL, which then translocates to the plasma membrane and executes necroptotic cell death by disrupting membrane integrity^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}.

In the context of neurodegenerative diseases, necroptosis has emerged as a significant contributor to neuronal loss. Research has demonstrated that all three core necroptosis proteins—RIPK1, RIPK3, and MLKL—are elevated in postmortem brain tissue from AD patients compared to age-matched controls^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}. This suggests that dysregulation of the necroptotic pathway may be a key driver of neuronal death in AD.

The RIPK1/RIPK3/MLKL Pathway

Activation and Initiation

The necroptosis pathway is initiated by death receptor engagement, most prominently by the TNF-α receptor^{5Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes2003 · Cell · DOI 10.1016/s0092-8674(03Open reference}. When TNF-α binds to its receptor (TNFR1), it triggers the formation of a complex known as complex I, which includes RIPK1, TNFR-associated death domain (TRADD), and TNF receptor-associated factor 2 (TRAF2)^{6TNF-α induces two distinct caspase-8-dependent cell death pathways2008 · Cell · DOI 10.1016/j.cell.2008.03.036Open reference}. Under normal conditions, this complex activates nuclear factor kappa B (NF-κB) signaling, promoting cell survival and inflammation resolution.

However, when caspase-8 activity is inhibited—whether pharmacologically or through endogenous inhibitors—the fate of the cell shifts toward necroptosis^{7Identification of RIP1 kinase as a specific cellular target of necrostatins2008 · Nature Chemical Biology · DOI 10.1038/nchembio.83Open reference}. In this scenario, RIPK1 recruits RIPK3 through shared death domain interactions, forming the necrosome complex. This complex then serves as a platform for MLKL phosphorylation.

The Necrosome Complex

The necrosome is a amyloid-like signaling platform that facilitates the trans-autophosphorylation of RIPK1 and RIPK3^{8'Necroptosis: an emerging form of programmed cell death'2022 · Critical Reviews in Oncology/Hematology · DOI 10.1016/j.critrevonc.2022.103759Open reference}. The formation of this complex is characterized by the phosphorylation of both kinases at specific serine residues. RIPK3 phosphorylates MLKL at Thr357 and Ser358 (human) or Ser345, Ser347, and Ser358 (mouse), which is essential for MLKL activation^{9Post-translational modifications of MLKL2023 · Cell · DOI 10.1016/j.cell.2023.08.024Open reference}.

The necrosome can form in the cytoplasm or at specific cellular compartments, including the mitochondria and endosomes. Research has shown that mitochondrial reactive oxygen species (ROS) can potentiate necrosome formation, creating a feed-forward loop that amplifies cell death signaling^{10Molecular mechanisms and pathophysiology of necrotic cell death2008 · Current Molecular Medicine · DOI 10.2174/156652408784221306Open reference}.

MLKL Execution

Once phosphorylated, MLKL undergoes a conformational change that exposes its four-helix bundle (4HB) domain, allowing it to interact with phospholipid membranes^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}0. The execution phase of necroptosis involves:

1. Oligomerization: Phosphorylated MLKL forms higher-order oligomers

2. Membrane translocation: These oligomers migrate to the plasma membrane and intracellular organelles

3. Pore formation: MLKL inserts into membranes, forming pores that disrupt ionic gradients

4. Cell swelling: Loss of membrane integrity leads to cellular swelling

5. Membrane rupture: Complete membrane disintegration releases intracellular contents

Necroptosis in Alzheimer’s Disease Pathogenesis

Evidence from Human Studies

Multiple studies have documented elevated necroptosis markers in AD brain tissue. A landmark study by Caccamo et al. demonstrated that RIPK1, RIPK3, and MLKL levels are significantly increased in the prefrontal cortex and hippocampus of AD patients compared to controls^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}1. Importantly, these increases correlated with disease severity, as measured by Braak staging and cognitive scores.

Further evidence comes from studies examining specific brain regions. The entorhinal cortex, which is particularly vulnerable in early AD, shows early activation of the necroptosis pathway^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}2. This suggests that necroptosis may contribute to the initial neuronal loss that underlies memory deficits in AD.

Mechanisms Linking Aβ to Necroptosis

Amyloid-beta (Aβ) peptides, the primary pathological aggregates in AD, can directly activate the necroptosis pathway. In vitro studies have shown that Aβ treatment of neurons leads to:

• Increased RIPK1 and RIPK3 phosphorylation: Aβ oligomers trigger the activation of both kinases^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}3

• MLKL translocation: Phosphorylated MLKL moves to the plasma membrane in Aβ-treated neurons^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}4

• Caspase-8 inhibition: Aβ can suppress caspase-8 activity, shifting the balance toward necroptosis^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}5

The link between Aβ and necroptosis involves multiple signaling pathways. Aβ activates TNF-α signaling and increases expression of death receptors, creating conditions favorable for necrosome formation^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}6. Additionally, Aβ-induced oxidative stress can damage mitochondria, releasing ROS that further promote necroptosis.

Tau Pathology and Necroptosis

While Aβ is considered the initiating factor in AD, tau pathology correlates more closely with cognitive decline. Recent research has revealed that pathological tau can also interact with the necroptosis pathway^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}7. Specifically:

• Tau phosphorylation: Hyperphosphorylated tau can interact with RIPK3, potentially enhancing necrosome formation^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}8

• Tau oligomers: These toxic species can activate necroptosis in neurons

• Spread mechanism: Necroptotic cell death may contribute to the spread of tau pathology by releasing extracellular tau aggregates

Pyroptosis: The Inflammatory Cell Death Companion

Pyroptosis is another form of programmed cell death that shares certain morphological features with necroptosis, particularly membrane rupture and release of inflammatory contents^{2'Programmed necrosis: backup to and competitor with apoptosis in the immune system'2011 · Nature Immunology · DOI 10.1038/ni.2157Open reference}9. However, the molecular mechanisms are distinct, and the two pathways can interconnect in AD.

Gasdermins and Pyroptosis

Pyroptosis is executed by gasdermin proteins, particularly gasdermin D (GSDMD)^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}0. The activation of pyroptosis involves inflammatory caspases (caspase-1, caspase-4, caspase-5, caspase-11) that cleave GSDMD, releasing its N-terminal domain from auto-inhibition. The N-terminal fragment then oligomerizes and forms pores in the plasma membrane^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}1.

In AD, pyroptosis is activated by:

1. Inflammasome assembly: Aβ and other DAMPs activate NLRP3 and other inflammasomes^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}2

2. Caspase-1 activation: This leads to processing of pro-inflammatory cytokines IL-1β and IL-18

3. Gasdermin D cleavage: Activated caspases cleave GSDMD, executing pyroptosis

Gasdermins Beyond Pyroptosis

Beyond GSDMD, other gasdermins have been implicated in neuronal death. Gasdermin E (GSDME, also known as DFNA5) can be activated by caspase-3 and has been implicated in secondary necrosis^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}3. Studies have shown increased GSDME expression in AD brain tissue, suggesting it may contribute to the progression of neuronal loss^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}4.

PANoptosis: The Integrated Cell Death Pathway

Recent research has identified PANoptosis (programmed cell death combining pyroptosis, apoptosis, and necroptosis) as a distinct inflammatory cell death pathway^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}5. This complex pathway involves the simultaneous activation of multiple cell death modalities and is regulated by the PANoptosome complex.

The PANoptosome

The PANoptosome is a large signaling platform that contains components from multiple cell death pathways, including:

• RIPK1 and RIPK3: Core necroptosis kinases^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}6

• Caspase-1: Central to pyroptosis

• Caspase-8: Can initiate apoptosis or block it, depending on context

• ASC: The adaptor protein that bridges inflammasome components

PANoptosis in AD

Evidence for PANoptosis in AD comes from studies showing co-activation of multiple cell death pathways. Wang et al. demonstrated that Aβ treatment of neurons triggers a PANoptotic response characterized by:

• Concurrent activation of caspase-8, caspase-3, caspase-1

• Phosphorylation of MLKL

• GSDMD cleavage^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}7

This integrated cell death response may explain the extensive neuronal loss observed in AD that cannot be attributed to apoptosis alone.

Therapeutic Implications

RIPK1 Inhibitors

Given the central role of necroptosis in AD pathogenesis, RIPK1 inhibitors have emerged as potential therapeutic agents^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}8. Several compounds have shown promise in preclinical models:

• Necrostatin-1 (Nec-1): A small molecule inhibitor of RIPK1 that has demonstrated neuroprotective effects in AD mouse models^{3Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase2012 · Cell · DOI 10.1016/j.cell.2011.11.031Open reference}9

• Dimethyl fumarate (DMF): An FDA-approved drug for multiple sclerosis that has been shown to inhibit RIPK1 and reduce neuroinflammation in AD models^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}0

Targeting Downstream Effectors

Beyond RIPK1, MLKL inhibitors are being developed as an alternative approach^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}1. These compounds would prevent the execution phase of necroptosis without affecting the upstream signaling that may have beneficial effects.

Modulating Pyroptosis

Inflammasome inhibitors represent another therapeutic avenue. Drugs targeting NLRP3 (such as MCC950) have shown promise in reducing neuroinflammation and neuronal loss in AD models^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}2.

Neuroinflammation Feedback Loops

A key feature of necroptosis in AD is its contribution to chronic neuroinflammation. When neurons undergo necroptosis, they release:

• Damage-associated molecular patterns (DAMPs): Including HMGB1, ATP, and DNA fragments^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}3

• Pro-inflammatory cytokines: Such as TNF-α, IL-1β, and IL-18

• Neurotoxic factors: That activate surrounding cells

This creates a vicious cycle where necroptosis-induced inflammation leads to more necroptosis and neuronal death^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}4. Microglia, the brain’s immune cells, become chronically activated in this environment, contributing to the neuroinflammatory state characteristic of AD.

Cross-Pathway Interactions

Necroptosis-Apoptosis Interplay

The decision between necroptosis and apoptosis is tightly regulated by caspase-8. When caspase-8 is active, it cleaves RIPK1, preventing necrosome formation and favoring apoptosis^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}5. However, in AD, various factors can suppress caspase-8 activity, pushing cells toward necroptosis.

Additionally, the BH3-only protein PUMA can modulate necroptosis by interacting with necrosome components^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}6. This intersection creates opportunities for therapeutic intervention at multiple points in the cell death cascade.

Interaction with Autophagy

Autophagy, the cellular recycling pathway, has complex relationships with necroptosis. While autophagy can protect against necroptosis by removing damaged mitochondria and reducing ROS, excessive autophagy can also contribute to cell death^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}7. In AD, autophagy is dysregulated, and this dysfunction may contribute to necroptosis susceptibility.

Research Frontiers

Biomarker Development

One active research area involves identifying necroptosis biomarkers that could aid in AD diagnosis and monitoring. Potential biomarkers include:

• Phosphorylated MLKL in cerebrospinal fluid: Indicative of ongoing necroptosis in the brain^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}8

• Circulating RIPK1 and RIPK3: Under investigation as peripheral markers

• Neurofilament light chain (NfL): A marker of neuronal damage that may reflect necroptotic activity

Genetic Factors

Genome-wide association studies (GWAS) have identified polymorphisms in necroptosis-related genes that may modify AD risk. Variants in the RIPK1 and MLKL genes are being investigated for their potential impact on disease progression^{4Necroptosis activation in Alzheimer's disease2017 · Nature Neuroscience · DOI 10.1038/nn.4608Open reference}9.

Sex Differences

Emerging research suggests sex differences in necroptosis susceptibility. Studies have shown that male mice show greater vulnerability to necroptosis in certain AD models, while females may have more robust compensatory mechanisms^{5Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes2003 · Cell · DOI 10.1016/s0092-8674(03Open reference}0. This could have implications for personalized therapeutic approaches.

Conclusion

Necroptosis represents a critical piece in the complex puzzle of neuronal loss in Alzheimer’s disease. The pathway’s activation by Aβ and tau, its contribution to neuroinflammation through DAMPs release, and its integration with pyroptosis and apoptosis through PANoptosis make it an attractive therapeutic target. Understanding the precise contributions of each cell death pathway in AD will be essential for developing effective neuroprotective strategies. Current efforts to develop RIPK1 inhibitors, MLKL blockers, and inflammasome modulators offer hope for disease-modifying treatments that can preserve neuronal function in Alzheimer’s disease.

See Also

• Amyloid-beta

External Links

• PubMed

• KEGG Pathways

Pathway Diagram

flowchart TD
    A["TNF-alpha Binding"]  -->  B["TNFR1 Activation"]
    B  -->  C["Complex I Formation"]
    C  -->  D["{NF-kappaB Activation<br/>Cell Survival}"]

    D  -->|"Caspase-8 Active"| E["Apoptosis"]
    D  -->|"Caspase-8 Inhibited"| F["Necrosome Formation"]

    F  -->  G["RIPK1-RIPK3 Interaction"]
    G  -->  H["RIPK1/RIPK3 Phosphorylation"]
    H  -->  I["MLKL Recruitment"]
    I  -->  J["MLKL Phosphorylation"]
    J  -->  K["MLKL Oligomerization"]
    K  -->  L["Membrane Translocation"]
    L  -->  M["Pore Formation"]
    M  -->  N["Cell Swelling"]
    N  -->  O["Membrane Rupture"]
    O  -->  P["Necroptosis"]

    Q["Abeta Oligomers"]  -->  R["TNFR1 Upregulation"]
    Q  -->  S["ROS Generation"]
    Q  -->  T["Caspase-8 Inhibition"]

    R  -->  F
    S  -->  F
    T  -->  F

    P  -->  U["DAMPs Release"]
    U  -->  V["Microglia Activation"]
    V  -->  W["Neuroinflammation"]
    W  -->  X["More Neuronal Death"]
    X  -->  Q

    style P fill:#ff6b6b,stroke:#333,stroke-width:2px
    style W fill:#feca57,stroke:#333,stroke-width:2px